摘要
目的观察信迪利单抗联合培美曲塞+顺铂化疗方案治疗非小细胞肺癌(NSCLC)的临床效果。方法回顾性分析93例NSCLC患者的临床资料,将54例采用培美曲塞+顺铂化疗方案治疗的患者纳入对照组,39例采用信迪利单抗联合培美曲塞+顺铂化疗方案治疗的患者纳入联合组。比较2组近期疗效、肿瘤标志物[细胞角蛋白19片段抗原(CYFRA21-1)、癌胚抗原(CEA)、癌抗原125(CA125)]水平、免疫功能指标(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及用药不良反应(胃肠道反应、造血系统异常、皮疹、肝肾功能异常、甲状腺功能异常)。结果治疗后,联合组疾病控制率(DCR)高于对照组,差异有统计学意义(P<0.05);2组客观缓解率(ORR)比较,差异无统计学意义(P>0.05)。治疗后,2组CYFRA21-1、CEA、CA125均较治疗前降低,且联合组低于对照组(P<0.05)。治疗后,联合组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前提高,CD8^(+)较治疗前降低;对照组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)均较治疗前降低,CD8^(+)较治疗前提高(P<0.05)。治疗过程中,2组不良反应发生率比较,差异均无统计学意义(P>0.05)。结论信迪利单抗联合培美曲塞+顺铂化疗方案治疗NSCLC的近期疗效良好,可降低肿瘤标志物水平,改善机体免疫功能,且用药安全性良好。
Objective To observe the clinical efficacy of Sintilimab combined with pemetrexed+cisplatin in the treatment of non-small cell lung cancer(NSCLC).Methods The clinical data of 93 NSCLC patients were retrospectively analyzed.54 patients who were treated with pemetrexed+cisplatin were included in the control group,and 39 patients who were treated with Sintilimab combined with pemetrexed+cisplatin were included in the combined group.The short-term efficacy,tumor marker[CYFRA21-1,Carcinoembryonic antigen,CA125]levels,immune function indicators(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and adverse drug reactions(gastrointestinal reactions,hematopoietic system abnormalities,rashes,liver and kidney dysfunction,thyroid dysfunction)were compared between the 2 groups.Results After treatment,the disease control rate(DCR)of the combined group was higher than that of the control group,with a statistical significant difference(P<0.05).There was no statistical significant difference in the objective response rate(ORR)between the 2 groups(P>0.05).After treatment,CYFRA21-1,CEA,and CA125 in both groups decreased compared to before treatment,and the combined group was lower than the control group(P<0.05).After treatment,the CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the combined group increased compared to before treatment,while CD8^(+)levels decreased compared to before treatment.The CD3^(+),CD4^(+),CD4^(+)/CD8^(+)levels in the control group decreased compared to before treatment,while CD8^(+)levels increased compared to before treatment(P<0.05).During the treatment process,there was no statistical significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Sintilimab combined with pemetrexed+cisplatin chemotherapy has good short-term efficacy in the treatment of NSCLC,which can reduce the level of tumor markers,improve the immune function of the body,and has good drug safety.
作者
尚宜星
朱雅静
肖淑娜
SHANG Yixing;ZHU Yajing;XIAO Shuna(The First Affiliated Hospital of Henan University of Science and Technology,Luoyang,471000)
出处
《实用癌症杂志》
2024年第9期1506-1509,1515,共5页
The Practical Journal of Cancer
